{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-385225","form_type":"8-K","ticker":"BBOT","cik":"0001869105","company_name":"BridgeBio Oncology Therapeutics, Inc.","filed_at":"2026-09-08T20:19:06+00:00","discovered_at":"2026-09-08T20:20:08.775976+00:00","generated_at":"2026-09-08T20:20:23.428227+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BBOT reports 75% ORR for BBO-8520 combo in 2L+ NSCLC; focuses on KRAS combos","bullets":["BBO-8520 + pembrolizumab: 75% ORR at 500 mg QD, 53% across doses in 2L+ G12C inhibitor-experienced NSCLC (N=17).","BBO-8520 monotherapy ORR 63% (26/41), DCR 100% (41/41), no grade 3 liver enzyme elevations in 2L+ G12C inhibitor-naive NSCLC.","$344.1M cash as of June 30, 2026; projected runway into 2028.","Strategic focus on BBO-8520 combo and BBO-11818/BBO-10203 combos in KRAS-mutant CRC and PDAC; data updates Q4 2026 and mid-2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-385225","json":"https://secwatch.observer/filing/0001193125-26-385225.json","markdown":"https://secwatch.observer/filing/0001193125-26-385225.md","text":"https://secwatch.observer/filing/0001193125-26-385225.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526385225/0001193125-26-385225-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526385225/d97546d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-08T20:20:23.428227+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}